Site icon OncologyTube

COMFORT II Study Shows Ruxolitinib as a Very Durable Treatment for MPN

Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how the COMFORT II Study Shows Ruxolitinib as a Very Durable Treatment for MPN from ASH 2015

Exit mobile version